###begin article-title 0
Plasminogen activator inhibitor-1 4G/5G gene polymorphism and primary open-angle glaucoma
###end article-title 0
###begin p 1
This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Purpose
###end title 2
###begin p 3
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 458 469 458 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 632 643 632 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
Alterations of the plasmin system have been suggested to participate in the multifactorial pathogenesis of primary open-angle glaucoma (POAG). The main physiological inhibitor of the plasmin system is plasminogen activator inhibitor-1 (PAI-1), which leads to decreased degradation of extracellular material. Interestingly, elevated PAI-1 levels in the aqueous humor of patients with POAG have been reported. A common polymorphism within the promoter region (PAI-1 4G/5G) has previously been shown to reduce the gene transcription rate of PAI-1. The purpose of the present study was to investigate a hypothesized association between PAI-1 4G/5G and the presence of POAG in a Caucasian population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 147 158 147 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 55 63 <span type="species:ncbi:9606">patients</span>
The present case-control study comprised 212 unrelated patients with POAG and 212 healthy control subjects, matched for age and sex. Genotyping of PAI-1 4G/5G polymorphisms was done using polymerase chain reaction.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 50 61 50 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 140 151 140 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 190 198 190 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G</italic>
###xml 99 107 <span type="species:ncbi:9606">patients</span>
Allelic frequencies and genotype distributions of PAI-1 4G/5G did not significantly differ between patients with POAG and control subjects (PAI-1 4G/5G: 29.7% versus 29.7%). Presence of the PAI-1 4G-allele was associated with a nonsignificant odds ratio of 0.98 (95% confidence interval: 0.74-1.30) for POAG.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 22 33 22 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 95 103 <span type="species:ncbi:9606">patients</span>
Our data suggest that PAI-1 4G/5G itself is unlikely to be a major risk factor among Caucasian patients with POAG.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r1">1</xref>
###xml 226 227 226 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r2">2</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r3">3</xref>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r4">4</xref>
Primary open-angle glaucoma (POAG; OMIM ) is one of the major causes of blindness throughout the world [1]. Elevated intraocular pressure (IOP) is the most important and so far the only therapeutically modifiable risk factor [2]. Accumulation of extracellular material (ECM) in the trabecular meshwork, which may be due to enhanced production or reduced degradation of ECM, has been suggested to lead to elevated IOP [3,4].
###end p 11
###begin p 12
###xml 281 282 281 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r5">5</xref>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r6">6</xref>
###xml 686 687 686 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r7">7</xref>
The serine protease plasmin has a central position in the fibrinolytic pathway, thereby restoring blood flow after thrombotic events. In addition, it also has a key role in the degradation and proteolysis of ECM via modulation of growth factors, cytokines, and metalloproteinases [5]. Plasminogen is converted to plasmin by the action of urokinase (u-PA) and tissue plasminogen activator (t-PA). The main physiological inhibitor of u-PA and t-PA is plasminogen activator inhibitor-1 (PAI-1; OMIM ), a glycoprotein composed of 379 amino acids, which forms a stable complex with both u-PA and t-PA [6]. It was shown that PAI-1 protects ECM from t-PA and plasminogen mediated degradation [7].
###end p 12
###begin p 13
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r8">8</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r11">11</xref>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r12">12</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r13">13</xref>
###xml 701 703 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r14">14</xref>
###xml 759 764 756 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 1025 1027 1022 1024 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 1028 1030 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 211 216 <span type="species:ncbi:9606">human</span>
###xml 477 482 <span type="species:ncbi:9606">human</span>
###xml 960 968 <span type="species:ncbi:9606">patients</span>
###xml 1015 1023 <span type="species:ncbi:9606">patients</span>
There is ample evidence for a physiological role of the plasmin system in the anterior segment of the eye and the trabecular outflow system in particular. Activity of u-PA, t-PA, and PAI-1 has been found in the human aqueous humor [8-11]. In an in vitro study, Shuman and coworkers [12] demonstrated that in trabecular meshwork cells, t-PA activity outweighs the inhibitor activity. Fuchshofer and coworkers [13] found a significant increase of PAI-1 expression in cultures of human TM cells after treatment with TGF-beta2, which leads to the expression of active matrix metalloproteinase-2 (MMP-2). Reduction of resistance to aqueous outflow was observed after perfusion of monkey eyes with plasmin [14]. It can thus be hypothesized that increased levels of PAI-1 may lead to decreased proteolysis of ECM in the trabecular meshwork, subsequently leading to an increase in IOP. Indeed, two recent studies reported elevated PAI-1 levels in the aqueous humor of patients with open-angle glaucoma compared to cataract patients [15,16].
###end p 13
###begin p 14
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 146 154 146 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 5G</italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r17">17</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r19">19</xref>
###xml 469 480 469 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 532 534 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r20">20</xref>
A common functional polymorphism within the promoter region due to a single guanosine insertion/deletion, 4G/5G (), has been identified [17]. The PAI-1 5G allele leads to binding of a repressor protein thereby decreasing gene transcription. Consequently, higher plasma PAI-1 concentrations have been found among homozygotes for the 4G- allele compared to heterozygotes and homozygotes for the 5G-allele [17-19]. However, a recent study found no association between the PAI-1 4G/5G polymorphism and expression of PAI-1 in platelets [20].
###end p 14
###begin p 15
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r21">21</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r22">22</xref>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
Since POAG is a disease with a high heritability as shown in population based studies [21,22], our study was set to investigate a hypothesized association between the PAI-1 4G/5G polymorphism and the presence of POAG.
###end p 15
###begin title 16
Methods
###end title 16
###begin p 17
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 88 100 <span type="species:ncbi:9606">participants</span>
###xml 232 244 <span type="species:ncbi:9606">participants</span>
The present study was comprised of 212 patients with POAG and 212 control subjects. All participants were seen at the Department of Ophthalmology, Medical University Graz (Graz, Autria) between September 2002 and November 2005. All participants were Caucasians from the same geographical area in the southern part of Austria. Informed consent was obtained from all subjects before enrollment. The study was conducted in accordance with the standards of the local ethics committee and the National Gene Technology Act.
###end p 17
###begin p 18
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
All patients underwent slit lamp biomicroscopy as well as testing for best corrected visual acuity, Goldmann applanation tonometry, gonioscopy, pachymetry, and standard automated perimetry (Interzeag Octopus 101, program G2) or - in cases of profoundly decreased visual acuity - Goldmann perimetry. In all patients, photographs of the optic disc were taken. POAG was defined by an intraocular pressure of at least 21 mmHg before the initiation of a pressure-lowering therapy, an open anterior chamber angle, optic disc changes characteristic for glaucoma (increased vertical cup/disc ratio of more than or equal to 0.7), visual field defects characteristic for glaucoma (inferior or superior arcuate scotoma, nasal step, or paracentral scotoma), and absence of conditions leading to secondary glaucoma. Optic discs were assessed by glaucoma specialists (GM and CF).
###end p 18
###begin p 19
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 379 391 <span type="species:ncbi:9606">participants</span>
The control group consisted of 212 patients with no morphological or functional damage indicative for primary or secondary open-angle or angle closure glaucoma. Control subjects were admitted to our department for cataract surgery and were matched to cases by sex and age (+/-3 years). Medical history concerning arterial hypertension and diabetes mellitus was obtained from all participants.
###end p 19
###begin title 20
Genotype determination
###end title 20
###begin p 21
###xml 91 96 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 618 619 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Genomic DNA was isolated from venous blood by standard methods and stored at -20 degreesC. PAI-1 genotypes were determined by a 5'-exonuclease assay (TaqMan, Applied Biosystems, Vienna, Austria). Primer and probe sets were designed and manufactured using Applied Biosystems 'Assay-by-Design' custom service (Applera, Austria). The polymerase chain reaction (PCR) was performed in a Primus 96 plus thermal cycler (MWG Biotech AG, Ebersberg, Germany) using a total volume of 5 mul containing 2.5 mul Universal Genotyping MasterMix (Applied Biosystems), 0.125 mul 40X Assay-by-Design mix (Applied Biosystems), 0.375 mul H2O, and 2 mul DNA. Reactions were overlaid with 15 mul of mineral oil. Cycling parameters were as follows primary denaturation was for 10 min at 94 degreesC followed by 40 cycles for 20 s at 92 degreesC and for 1 min at 60 degreesC. Fluorescence was measured in a lambda Fluoro 320 Plus plate reader (MWG Biotech AG) using excitation/emission filters of 485 nm/530 nm for FAM-labeled probes (4G-allele) and 530 nm/572 nm for VIC-labeled probes (5G-allele). The data were exported into Excel format and depicted and analyzed as a scatter plot.
###end p 21
###begin p 22
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r23">23</xref>
To validate the genotyping method, we also determined PAI-1 genotypes of 24 samples, which had been analyzed previously by a polymerase chain reaction and endonuclease digestion method [23]. Results of both methods were consistent in all samples.
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 249 250 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Descriptive statistics were used to calculate frequencies and percentages of discrete variables. Continuous data are given as mean+/-standard deviation (SD). Means were compared using the Mann-Whitney test. Proportions of groups were compared by chi2 test. Odds ratio (OR) and 95% confidence interval (95% CI) were calculated by logistic regression. The criterion for statistical significance was p</=0.05. Statistical analysis was done using the SPSS statistical package (SPSS, version 14.0, Chicago, Illinois).
###end p 24
###begin title 25
Results
###end title 25
###begin p 26
###xml 296 303 292 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t1">Table 1</xref>
###xml 32 40 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 253 261 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">Patients</span>
###xml 522 530 <span type="species:ncbi:9606">patients</span>
###xml 602 610 <span type="species:ncbi:9606">patients</span>
###xml 682 690 <span type="species:ncbi:9606">patients</span>
###xml 735 743 <span type="species:ncbi:9606">patients</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 847 855 <span type="species:ncbi:9606">patients</span>
###xml 902 910 <span type="species:ncbi:9606">patients</span>
The present study comprised 212 patients (125 female and 87 male) with POAG and 212 controls (125 female and 87 male). The mean age of patients was 71.5+/-9.8 years, and the mean age of control subjects was 70.9+/-9.6 years. Clinical characteristics of patients and control subjects are shown in Table 1. Patients had a mean deviation of 11.5+/-6.7 dB, a mean loss of variance of 38.0+/-27.6 square decibel, a mean intraocular pressure of 21.8+/-15.4 mmHg, and a mean cup disc ratio of 0.79+/-0.13 in the worse eye. In 34 patients (16%), a trabeculectomy with mitomycin C has been performed, and in 19 patients (9%), a transscleral cyclophotocoagulation has been performed while 44 patients (20.8%) had both interventions. Seventy-two patients (34%) were treated with prostaglandin analogs, 44 patients (20.8%) were treated with beta-blockers, 23 patients (10.8%) were treated with brimonidine, and 17 patients (8%) were treated with carbonic anhydrase inhibitors.
###end p 26
###begin title 27
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Clinical characteristics of patients with primary open-angle glaucoma and controls.
###end title 27
###begin p 28
*Numbers are given as n (%).
###end p 28
###begin p 29
###xml 89 100 89 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 174 181 174 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="t2">Table 2</xref>
###xml 200 208 200 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G</italic>
###xml 378 389 378 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 133 141 <span type="species:ncbi:9606">patients</span>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
No significant differences in either genotype distribution or allelic frequencies of the PAI-1 4G/5G polymorphism were found between patients with POAG and control subjects (Table 2). Presence of the PAI-1 4G-allele was associated with an odds ratio of 0.98 (95% CI: 0.74-1.30) for POAG. The present study had a statistical power of 0.80 to detect an odds ratio of 1.77 for the PAI-1 4G/5G genotype in patients with POAG.
###end p 29
###begin title 30
###xml 46 51 46 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
Genotype distribution and allele frequency of PAI-1 4G/5G polymorphism.
###end title 30
###begin p 31
*Numbers for genotypes are n (%)
###end p 31
###begin p 32
###xml 219 221 219 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r24">24</xref>
###xml 222 224 222 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r25">25</xref>
The observed genotype distributions did not deviate from those predicted by the Hardy-Weinberg equilibrium, and for control subjects, the genotype distributions were similar to those reported for Caucasian populations [24,25].
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r15">15</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r16">16</xref>
###xml 652 663 652 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
The balance between plasmin activators and inhibitors is of utmost importance not only for vascular homeostasis but also for extracellular proteolysis. Alterations of the plasmin system potentially leading to reduced degradation of ECM in the trabecular meshwork have been implicated in the pathogenesis of POAG. Interestingly, elevated levels of PAI-1 in the aqueous humor of patients with POAG were reported only recently [15,16]. Gene polymorphisms leading to increased synthesis of PAI-1 may thus contribute to the pathogenesis of POAG. To the best of our knowledge, the present study is the first to investigate a hypothesized association between PAI-1 4G/5G and the presence of POAG.
###end p 34
###begin p 35
###xml 13 24 13 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 316 327 316 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 48 56 <span type="species:ncbi:9606">patients</span>
###xml 340 348 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
Genotypes of PAI-1 4G/5G were determined in 212 patients with POAG and 212 control subjects that were matched for age and sex. Allelic frequencies as well as genotype distributions did not significantly differ between both groups. As the study has a statistical power of 0.80 to detect an odds ratio of 1.77 for the PAI-1 4G/5G genotype in patients with POAG, our data suggest that the investigated polymorphism is unlikely a major genetic risk factor for POAG in Caucasian patients.
###end p 35
###begin p 36
###xml 294 299 294 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r26">26</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r28">28</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r29">29</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r32">32</xref>
###xml 565 567 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 568 570 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r35">35</xref>
###xml 745 747 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="r33">33</xref>
###xml 777 782 767 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1</italic>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Potentially, elevation of the PAI-1 level in the aqueous humor may result from reduced aqueous humor turnover in patients with POAG. Furthermore, synthesis of PAI-1 is regulated by various factors. Hyperglycemia as well as insulin and insulin precursor molecules stimulate the transcription of PAI-1 [26-28]. Angiotensin II, very low density lipoproteins, and unsaturated fatty acids induce the expression of PAI-1 whereas estrogen suppresses synthesis of PAI-1 [29-32]. Moreover, cytokines like TGF-beta2 and tumor necrosis factor-alpha increase PAI-1 expression [33-35]. In an in vitro study, Fleenor and coworkers provided evidence that treatment of trabecular meshwork with TGF-beta2 increased secretion of PAI-1, which led to elevated IOP [33]. Thus, our finding that the PAI-1 4G/5G polymorphism is not associated with an increased risk for POAG does not exclude a substantial role of PAI-1 in the pathogenesis of POAG.
###end p 36
###begin p 37
###xml 91 102 91 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PAI-1 4G/5G</italic>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
In conclusion, no statistically significant difference in the genotype distribution of the PAI-1 4G/5G polymorphism was found between patients with POAG and control subjects, which strongly suggests that this polymorphism itself is unlikely a major risk-factor for POAG.
###end p 37
###begin title 38
Acknowlegments
###end title 38
###begin p 39
The authors thank Ms. Trummer and Ms. Wachswender for their skillful technical assistance.
###end p 39
###begin title 40
References
###end title 40
###begin article-title 41
Global data on visual impairment in the year 2002.
###end article-title 41
###begin article-title 42
The advanced glaucoma intervention study (AGIS): 7. the relationship between control of intraocular pressure and visual field deterioration.
###end article-title 42
###begin article-title 43
Juxtacanalicular tissue in primary open angle glaucoma and in nonglaucomatous normals.
###end article-title 43
###begin article-title 44
Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm's canal in normal- and glaucomatous eyes.
###end article-title 44
###begin article-title 45
The plasminogen activator/plasmin system.
###end article-title 45
###begin article-title 46
Plasminogen-activator inhibitor type 1 and coronary artery disease.
###end article-title 46
###begin article-title 47
Matrix plasminogen activator inhibitor. Modulation of the extracellular proteolytic environment.
###end article-title 47
###begin article-title 48
###xml 40 45 <span type="species:ncbi:9606">human</span>
Urokinase-type plasminogen activator in human aqueous humor.
###end article-title 48
###begin article-title 49
###xml 41 46 <span type="species:ncbi:9606">human</span>
Tissue plasminogen activator activity in human aqueous humor.
###end article-title 49
###begin article-title 50
###xml 65 70 <span type="species:ncbi:9606">human</span>
Plasminogen activator and PAI. Detection in aqueous humor of the human eye.
###end article-title 50
###begin article-title 51
###xml 71 76 <span type="species:ncbi:9606">human</span>
Increased basal levels of free plasminogen activator activity found in human aqueous humor.
###end article-title 51
###begin article-title 52
###xml 41 46 <span type="species:ncbi:9606">human</span>
Tissue plasminogen activator in cultured human trabecular meshwork cells. Predominance of enzyme over plasminogen activator inhibitor.
###end article-title 52
###begin article-title 53
###xml 27 32 <span type="species:ncbi:9606">human</span>
The effect of TGF-beta2 on human trabecular meshwork extracellular proteolytic system.
###end article-title 53
###begin article-title 54
Effect of plasmin on outflow resistance in the primate eye.
###end article-title 54
###begin article-title 55
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma.
###end article-title 55
###begin article-title 56
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.
###end article-title 56
###begin article-title 57
4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study.
###end article-title 57
###begin article-title 58
Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.
###end article-title 58
###begin article-title 59
Plasminogen activator inhibitor 1 expression in platelets is not influenced by the 4G/5G promoter polymorphism.
###end article-title 59
###begin article-title 60
Family history and risk of primary open angle glaucoma. The Baltimore Eye Survey.
###end article-title 60
###begin article-title 61
Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study.
###end article-title 61
###begin article-title 62
An alternative method for PAI-1 promoter polymorphism (4G/5G) typing.
###end article-title 62
###begin article-title 63
###xml 77 85 <span type="species:ncbi:9606">children</span>
4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia.
###end article-title 63
###begin article-title 64
Role of angiotensin-converting enzyme insertion/deletion and plasminogen activator inhibitor-1 4G/5G gene polymorphisms in retinal vein occlusion.
###end article-title 64
###begin article-title 65
Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.
###end article-title 65
###begin article-title 66
###xml 109 114 <span type="species:ncbi:9606">human</span>
Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose.
###end article-title 66
###begin article-title 67
Stimulation by proinsulin of expression of plasminogen activator inhibitor type-I in endothelial cells.
###end article-title 67
###begin article-title 68
Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study.
###end article-title 68
###begin article-title 69
Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells.
###end article-title 69
###begin article-title 70
VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor.
###end article-title 70
###begin article-title 71
Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.
###end article-title 71
###begin article-title 72
###xml 28 33 <span type="species:ncbi:9606">human</span>
TGFbeta2-induced changes in human trabecular meshwork: implications for intraocular pressure.
###end article-title 72
###begin article-title 73
###xml 208 213 <span type="species:ncbi:9606">human</span>
Tumor necrosis factor-alpha and troglitazone regulate plasminogen activator inhibitor type 1 production through extracellular signal-regulated kinase- and nuclear factor-kappaB-dependent pathways in cultured human umbilical vein endothelial cells.
###end article-title 73
###begin article-title 74
###xml 119 124 <span type="species:ncbi:9606">human</span>
Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
###end article-title 74

